Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen

Uri Ben-David; Qing Fen Gan; Tamar Golan-Lev; Payal Arora; Ofra Yanuka; Yifat S. Oren; Alicia Leikin-Frenkel; Martin Graf; Ralph Garippa; Markus Boehringer; Gianni Gromo; Nissim Benvenisty

doi:10.1016/j.stem.2012.11.015

Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen

Uri Ben-David
, Qing Fen Gan
, Tamar Golan-Lev
, Payal Arora
, Ofra Yanuka
, Yifat S. Oren
, Alicia Leikin-Frenkel
, Martin Graf
, Ralph Garippa
, Markus Boehringer
, Gianni Gromo
, Nissim Benvenisty^*

^*Corresponding author for this work

Department of Genetics

Research output: Contribution to journal › Article › peer-review

278 Scopus citations

Abstract

The use of human pluripotent stem cells (hPSCs) in cell therapy is hindered by the tumorigenic risk from residual undifferentiated cells. Here we performed a high-throughput screen of over 52,000 small molecules and identified 15 pluripotent cell-specific inhibitors (PluriSIns), nine of which share a common structural moiety. The PluriSIns selectively eliminated hPSCs while sparing a large array of progenitor and differentiated cells. Cellular and molecular analyses demonstrated that the most selective compound, PluriSIn #1, induces ER stress, protein synthesis attenuation, and apoptosis in hPSCs. Close examination identified this molecule as an inhibitor of stearoyl-coA desaturase (SCD1), the key enzyme in oleic acid biosynthesis, revealing a unique role for lipid metabolism in hPSCs. PluriSIn #1 was also cytotoxic to mouse blastocysts, indicating that the dependence on oleate is inherent to the pluripotent state. Finally, application of PluriSIn #1 prevented teratoma formation from tumorigenic undifferentiated cells. These findings should increase the safety of hPSC-based treatments.

Original language	English
Pages (from-to)	167-179
Number of pages	13
Journal	Cell Stem Cell
Volume	12
Issue number	2
DOIs	https://doi.org/10.1016/j.stem.2012.11.015
State	Published - 7 Feb 2013

Bibliographical note

Funding Information:
The authors would like to thank Hong Ma and Adva Maimon for their assistance with tissue culture; Dr. Eric Chiao, Dr. Josh Babiarz, Dr. Jenny Cohen, and Sei Kameoka for their assistance with assay development; Sean Walker for his assistance with the liquid handler; Dr. Ann Hoffman for her assistance with microscopy imaging; Dr. Rachel Eiges for her assistance with the in vitro embryonic development assay and for critically reading the manuscript; Dr. Sonia Steiner-Mordoch and Professor Oded Meyuhas for their assistance with the protein synthesis inhibition assay; Dr. Simona Ceccarelli for her assistance with the chemical analysis of compounds; Tamar Shiloach for her assistance with apoptosis assays; Dr. Eran Meshorer for the mouse ESCs and for critically reading the manuscript; Oded Kopper for the CSES2-SO2/3 cells; Professor Batsheva Kerem, Dr. Kyle Kolaja, Dr. Jacques Mizrahi, and Dr. David Mark for fruitful discussions and helpful suggestions. N.B. is the Herbert Cohn Chair in Cancer Research. U.B.-D. is a Clore Fellow. This work was supported by a grant from Hoffmann La Roche-Yissum collaboration. Q.F.G., M.G., M.B., and G.G. are employees of the company. R.G. and P.A. are former employees of the company.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.stem.2012.11.015

Cite this

Ben-David, U., Gan, Q. F., Golan-Lev, T., Arora, P., Yanuka, O., Oren, Y. S., Leikin-Frenkel, A., Graf, M., Garippa, R., Boehringer, M., Gromo, G., & Benvenisty, N. (2013). Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen. Cell Stem Cell, 12(2), 167-179. https://doi.org/10.1016/j.stem.2012.11.015

@article{983539807db74c59b0f82568edecca0c,

title = "Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen",

abstract = "The use of human pluripotent stem cells (hPSCs) in cell therapy is hindered by the tumorigenic risk from residual undifferentiated cells. Here we performed a high-throughput screen of over 52,000 small molecules and identified 15 pluripotent cell-specific inhibitors (PluriSIns), nine of which share a common structural moiety. The PluriSIns selectively eliminated hPSCs while sparing a large array of progenitor and differentiated cells. Cellular and molecular analyses demonstrated that the most selective compound, PluriSIn \#1, induces ER stress, protein synthesis attenuation, and apoptosis in hPSCs. Close examination identified this molecule as an inhibitor of stearoyl-coA desaturase (SCD1), the key enzyme in oleic acid biosynthesis, revealing a unique role for lipid metabolism in hPSCs. PluriSIn \#1 was also cytotoxic to mouse blastocysts, indicating that the dependence on oleate is inherent to the pluripotent state. Finally, application of PluriSIn \#1 prevented teratoma formation from tumorigenic undifferentiated cells. These findings should increase the safety of hPSC-based treatments.",

author = "Uri Ben-David and Gan, \{Qing Fen\} and Tamar Golan-Lev and Payal Arora and Ofra Yanuka and Oren, \{Yifat S.\} and Alicia Leikin-Frenkel and Martin Graf and Ralph Garippa and Markus Boehringer and Gianni Gromo and Nissim Benvenisty",

note = "Funding Information: The authors would like to thank Hong Ma and Adva Maimon for their assistance with tissue culture; Dr. Eric Chiao, Dr. Josh Babiarz, Dr. Jenny Cohen, and Sei Kameoka for their assistance with assay development; Sean Walker for his assistance with the liquid handler; Dr. Ann Hoffman for her assistance with microscopy imaging; Dr. Rachel Eiges for her assistance with the in vitro embryonic development assay and for critically reading the manuscript; Dr. Sonia Steiner-Mordoch and Professor Oded Meyuhas for their assistance with the protein synthesis inhibition assay; Dr. Simona Ceccarelli for her assistance with the chemical analysis of compounds; Tamar Shiloach for her assistance with apoptosis assays; Dr. Eran Meshorer for the mouse ESCs and for critically reading the manuscript; Oded Kopper for the CSES2-SO2/3 cells; Professor Batsheva Kerem, Dr. Kyle Kolaja, Dr. Jacques Mizrahi, and Dr. David Mark for fruitful discussions and helpful suggestions. N.B. is the Herbert Cohn Chair in Cancer Research. U.B.-D. is a Clore Fellow. This work was supported by a grant from Hoffmann La Roche-Yissum collaboration. Q.F.G., M.G., M.B., and G.G. are employees of the company. R.G. and P.A. are former employees of the company. ",

year = "2013",

month = feb,

day = "7",

doi = "10.1016/j.stem.2012.11.015",

language = "אנגלית",

volume = "12",

pages = "167--179",

journal = "Cell Stem Cell",

issn = "1934-5909",

publisher = "Cell Press",

number = "2",

}

Ben-David, U, Gan, QF, Golan-Lev, T, Arora, P, Yanuka, O, Oren, YS, Leikin-Frenkel, A, Graf, M, Garippa, R, Boehringer, M, Gromo, G & Benvenisty, N 2013, 'Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen', Cell Stem Cell, vol. 12, no. 2, pp. 167-179. https://doi.org/10.1016/j.stem.2012.11.015

TY - JOUR

T1 - Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen

AU - Ben-David, Uri

AU - Gan, Qing Fen

AU - Golan-Lev, Tamar

AU - Arora, Payal

AU - Yanuka, Ofra

AU - Oren, Yifat S.

AU - Leikin-Frenkel, Alicia

AU - Graf, Martin

AU - Garippa, Ralph

AU - Boehringer, Markus

AU - Gromo, Gianni

AU - Benvenisty, Nissim

N1 - Funding Information: The authors would like to thank Hong Ma and Adva Maimon for their assistance with tissue culture; Dr. Eric Chiao, Dr. Josh Babiarz, Dr. Jenny Cohen, and Sei Kameoka for their assistance with assay development; Sean Walker for his assistance with the liquid handler; Dr. Ann Hoffman for her assistance with microscopy imaging; Dr. Rachel Eiges for her assistance with the in vitro embryonic development assay and for critically reading the manuscript; Dr. Sonia Steiner-Mordoch and Professor Oded Meyuhas for their assistance with the protein synthesis inhibition assay; Dr. Simona Ceccarelli for her assistance with the chemical analysis of compounds; Tamar Shiloach for her assistance with apoptosis assays; Dr. Eran Meshorer for the mouse ESCs and for critically reading the manuscript; Oded Kopper for the CSES2-SO2/3 cells; Professor Batsheva Kerem, Dr. Kyle Kolaja, Dr. Jacques Mizrahi, and Dr. David Mark for fruitful discussions and helpful suggestions. N.B. is the Herbert Cohn Chair in Cancer Research. U.B.-D. is a Clore Fellow. This work was supported by a grant from Hoffmann La Roche-Yissum collaboration. Q.F.G., M.G., M.B., and G.G. are employees of the company. R.G. and P.A. are former employees of the company.

PY - 2013/2/7

Y1 - 2013/2/7

N2 - The use of human pluripotent stem cells (hPSCs) in cell therapy is hindered by the tumorigenic risk from residual undifferentiated cells. Here we performed a high-throughput screen of over 52,000 small molecules and identified 15 pluripotent cell-specific inhibitors (PluriSIns), nine of which share a common structural moiety. The PluriSIns selectively eliminated hPSCs while sparing a large array of progenitor and differentiated cells. Cellular and molecular analyses demonstrated that the most selective compound, PluriSIn #1, induces ER stress, protein synthesis attenuation, and apoptosis in hPSCs. Close examination identified this molecule as an inhibitor of stearoyl-coA desaturase (SCD1), the key enzyme in oleic acid biosynthesis, revealing a unique role for lipid metabolism in hPSCs. PluriSIn #1 was also cytotoxic to mouse blastocysts, indicating that the dependence on oleate is inherent to the pluripotent state. Finally, application of PluriSIn #1 prevented teratoma formation from tumorigenic undifferentiated cells. These findings should increase the safety of hPSC-based treatments.

AB - The use of human pluripotent stem cells (hPSCs) in cell therapy is hindered by the tumorigenic risk from residual undifferentiated cells. Here we performed a high-throughput screen of over 52,000 small molecules and identified 15 pluripotent cell-specific inhibitors (PluriSIns), nine of which share a common structural moiety. The PluriSIns selectively eliminated hPSCs while sparing a large array of progenitor and differentiated cells. Cellular and molecular analyses demonstrated that the most selective compound, PluriSIn #1, induces ER stress, protein synthesis attenuation, and apoptosis in hPSCs. Close examination identified this molecule as an inhibitor of stearoyl-coA desaturase (SCD1), the key enzyme in oleic acid biosynthesis, revealing a unique role for lipid metabolism in hPSCs. PluriSIn #1 was also cytotoxic to mouse blastocysts, indicating that the dependence on oleate is inherent to the pluripotent state. Finally, application of PluriSIn #1 prevented teratoma formation from tumorigenic undifferentiated cells. These findings should increase the safety of hPSC-based treatments.

UR - https://www.scopus.com/pages/publications/84873572366

U2 - 10.1016/j.stem.2012.11.015

DO - 10.1016/j.stem.2012.11.015

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 23318055

AN - SCOPUS:84873572366

SN - 1934-5909

VL - 12

SP - 167

EP - 179

JO - Cell Stem Cell

JF - Cell Stem Cell

IS - 2

ER -

Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this